Equity Profile

PTGX

Protagonist Therapeutics, Inc.

Health CareBiotechnology$8.4B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Protagonist Therapeutics, Inc. is a biotechnology company focused on developing therapies for various diseases, particularly in the areas of autoimmune and gastrointestinal disorders....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth is crucial for assessing the company's ability to expand its market presence and sustain operations.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

PTGX Q2-2026 Earnings Preview

Context

Company Snapshot

Protagonist Therapeutics, Inc. is a biotechnology company focused on developing therapies for various diseases, particularly in the areas of autoimmune and gastrointestinal disorders. As part of the health care sector, its innovations could significantly impact patient care and treatment options.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+397.37%

Avg Stock Reaction

-0.19%

Last Quarter Recap

In Q1 2026, Protagonist reported an EPS of $0.05, significantly beating expectations of a loss. However, revenue details were not disclosed, leaving some uncertainty about overall performance.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, investors are cautiously optimistic about Protagonist's upcoming earnings, especially after a surprising EPS beat last quarter. However, the lack of guidance and revenue details creates uncertainty.

Bull Case

If Protagonist continues to show strong EPS performance and reveals positive revenue growth, it could boost investor confidence and drive the stock higher.

Bear Case

Conversely, if the company fails to meet expectations or provides disappointing insights into revenue, it could lead to a decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the revenue figure for Q2 2026?

Revenue is critical for understanding the company's growth trajectory and overall financial health, especially after the last quarter's EPS surprise.

Will management provide guidance for the upcoming quarters?

Guidance can significantly influence investor sentiment and expectations, impacting stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Protagonist to deliver strong revenue growth based on recent developments in its pipeline.

Supporting Evidence

The last quarter's EPS surprise suggests operational efficiency that could translate into revenue growth.

The options market is pricing for significant movement, indicating that investors expect more than just a typical performance.

Historical performance shows that Protagonist has the potential to exceed expectations, as seen in prior quarters.

Key Risk

If revenue comes in significantly below expectations, it could undermine the positive sentiment around the stock.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for continued profitability against the uncertainty of revenue growth.

Bull Confirmed If

A revenue figure that exceeds analyst expectations would confirm the bullish outlook.

Bear Confirmed If

A revenue figure that falls short of expectations would solidify the bearish case.

Pre-Earnings Positioning

Options Market

Implied Move

±18.21%

Historical Avg

±1.3%

Pricing rich

The options market is pricing in a significant potential move, indicating that investors expect volatility around the earnings announcement.

Options are pricing ±18.2% while PTGX has averaged ±1.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

39.0%

Calls (18K)P/C Ratio: 2.50Puts (100)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Protagonist beats expectations and raises guidance, history suggests a potential stock increase of around 1.27% on the first day.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may experience muted movement.

Miss

Should the company miss expectations, history indicates a potential decline of approximately 0.80% on the first day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline advancements and their potential market impact.
2Details on revenue performance and growth drivers for the quarter.
3Management's outlook on future earnings and market conditions.
4Insights into competitive positioning within the biotechnology sector.
5Any commentary on partnerships or collaborations that could enhance growth.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

Protagonist Therapeutics, Inc. is a biotechnology company focused on developing therapies for various diseases, particularly in the areas of autoimmune and gastrointestinal disorders....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth is crucial for assessing the company's ability to expand its market presence and sustain operations.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

PTGX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+397.37%

Avg Stock Reaction

-0.19%

Last Quarter Recap

In Q1 2026, Protagonist reported an EPS of $0.05, significantly beating expectations of a loss. However, revenue details were not disclosed, leaving some uncertainty about overall performance.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Protagonist continues to show strong EPS performance and reveals positive revenue growth, it could boost investor confidence and drive the stock higher.

Bear Case

Conversely, if the company fails to meet expectations or provides disappointing insights into revenue, it could lead to a decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the revenue figure for Q2 2026?

Revenue is critical for understanding the company's growth trajectory and overall financial health, especially after the last quarter's EPS surprise.

Will management provide guidance for the upcoming quarters?

Guidance can significantly influence investor sentiment and expectations, impacting stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Protagonist to deliver strong revenue growth based on recent developments in its pipeline.

Supporting Evidence

The last quarter's EPS surprise suggests operational efficiency that could translate into revenue growth.

The options market is pricing for significant movement, indicating that investors expect more than just a typical performance.

Historical performance shows that Protagonist has the potential to exceed expectations, as seen in prior quarters.

Key Risk

If revenue comes in significantly below expectations, it could undermine the positive sentiment around the stock.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for continued profitability against the uncertainty of revenue growth.

Bull Confirmed If

A revenue figure that exceeds analyst expectations would confirm the bullish outlook.

Bear Confirmed If

A revenue figure that falls short of expectations would solidify the bearish case.

Pre-Earnings Positioning

Options Market

Implied Move

±18.21%

Historical Avg

±1.3%

Pricing rich

The options market is pricing in a significant potential move, indicating that investors expect volatility around the earnings announcement.

Options are pricing ±18.2% while PTGX has averaged ±1.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

39.0%

Calls (18K)P/C Ratio: 2.50Puts (100)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Protagonist beats expectations and raises guidance, history suggests a potential stock increase of around 1.27% on the first day.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may experience muted movement.

Miss

Should the company miss expectations, history indicates a potential decline of approximately 0.80% on the first day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline advancements and their potential market impact.
2Details on revenue performance and growth drivers for the quarter.
3Management's outlook on future earnings and market conditions.
4Insights into competitive positioning within the biotechnology sector.
5Any commentary on partnerships or collaborations that could enhance growth.